cbdMD, Inc. Q3 2026 Earnings Recap

Shares fell 3.6% after cbdMD reported significant margin pressure and cautious near-term outlook driven by integration costs from the Bluebird acquisition and accelerated investment in the new CMS substance access channel. Investors questioned the sustainability of growth given ongoing regulatory headwinds and the near-term negative earnings impact.

Key Takeaways

• Revenue grew 19% year-over-year to $5.6 million, with a 12% sequential increase, driven partly by the recent Bluebird Botanicals acquisition.
• Core cbdMD business excluding Bluebird showed modest growth of $0.5 million year-over-year and $0.3 million sequentially, the highest quarterly revenue since December 2023.
• Wholesale channel expanded strongly, up 65% year-over-year to 33% of total revenue, led by cbdMD brand and Oasis TSC beverage.
• The Bluebird acquisition incurred transition and integration costs in Q2, suppressing earnings, though March saw positive contribution beginning.
• Accelerated investment in the CMS Medicare beneficiary engagement initiative created near-term expenses, delaying revenue realization, with management emphasizing a longer 12-18 month horizon for payoffs amid ongoing state regulatory volatility.